|
1
|
Condelli V, Crispo F, Pietrafesa M,
Lettini G, Matassa DS, Esposito F, Landriscina M and Maddalena F:
HSP90 molecular chaperones, metabolic rewiring, and epigenetics:
Impact on tumor progression and perspective for anticancer therapy.
Cells. 8:5322019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hoter A, El-Sabban ME and Naim HY: The
HSP90 family: Structure, regulation, function, and implications in
health and disease. Int J Mol Sci. 19:25602018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Whitesell L and Lindquist SL: HSP90 and
the chaperoning of cancer. Nat Rev Cancer. 5:761–772. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang H and Burrows F: Targeting multiple
signal transduction pathways through inhibition of Hsp90. J Mol Med
(Berl). 82:488–499. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chiosis G: Targeting chaperones in
transformed systems-a focus on HSP90 and cancer. Expert Opin Ther
Targets. 10:37–50. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Workman P: Combinatorial attack on
multistep oncogenesis by inhibiting the Hsp90 molecular chaperone.
Cancer Lett. 206:149–157. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Csermely P, Schnaider T, Soti C, Prohaszka
Z and Nardai G: The 90-kDa molecular chaperone family: Structure,
function, and clinical applications. A comprehensive review.
Pharmacol Ther. 79:129–168. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Prodromou C, Roe SM, O'Brien R, Ladbury
JE, Piper PW and Pearl LH: Identification and structural
characterization of the ATP/ADP-binding site in the Hsp90 molecular
chaperone. Cell. 90:65–75. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Meyer P, Prodromou C, Hu B, Vaughan C, Roe
SM, Panaretou B, Piper PW and Pearl LH: Structural and functional
analysis of the middle segment of hsp90: Implications for ATP
hydrolysis and client protein and cochaperone interactions. Mol
Cell. 11:647–658. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Minami Y, Kimura Y, Kawasaki H, Suzuki K
and Yahara I: The carboxy-terminal region of mammalian HSP90 is
required for its dimerization and function in vivo. Mol Cell Biol.
14:1459–1464. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Panaretou B, Prodromou C, Roe SM, O'Brien
R, Ladbury JE, Piper PW and Pearl LH: ATP binding and hydrolysis
are essential to the function of the Hsp90 molecular chaperone in
vivo. EMBO J. 17:4829–4836. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vorherr T, Knopfel L, Hofmann F, Mollner
S, Pfeuffer T and Carafoli E: The calmodulin binding domain of
nitric oxide synthase and adenylyl cyclase. Biochemistry.
32:6081–6088. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jackson SE: Hsp90: Structure and function.
Top Curr Chem. 328:155–240. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li J, Soroka J and Buchner J: The Hsp90
chaperone machinery: Conformational dynamics and regulation by
co-chaperones. Biochim Biophys Acta. 1823:624–635. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Marzec M, Eletto D and Argon Y: GRP94: An
HSP90-like protein specialized for protein folding and quality
control in the endoplasmic reticulum. Biochim Biophys Acta.
1823:774–787. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Amoroso MR, Matassa DS, Sisinni L, Lettini
G, Landriscina M and Esposito F: TRAP1 revisited: Novel
localizations and functions of a ‘next-generation’ biomarker
(review). Int J Oncol. 45:969–977. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Soga S, Akinaga S and Shiotsu Y: Hsp90
inhibitors as anti-cancer agents, from basic discoveries to
clinical development. Curr Pharm Des. 19:366–376. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sanchez J, Carter TR, Cohen MS and Blagg
BSJ: Old and new approaches to target the Hsp90 chaperone. Curr
Cancer Drug Targets. 20:253–270. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Koren J III and Blagg BSJ: The right tool
for the job: An overview of Hsp90 inhibitors. Adv Exp Med Biol.
1243:135–146. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jhaveri K, Taldone T, Modi S and Chiosis
G: Advances in the clinical development of heat shock protein 90
(Hsp90) inhibitors in cancers. Biochim Biophys Acta. 1823:742–755.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dutta R and Inouye M: GHKL, an emergent
ATPase/kinase superfamily. Trends Biochem Sci. 25:24–28. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Meng X, Devin J, Sullivan WP, Toft D,
Baulieu EE and Catelli MG: Mutational analysis of Hsp90 alpha
dimerization and subcellular localization: Dimer disruption does
not impede ‘in vivo’ interaction with estrogen receptor. J Cell
Sci. 109:1677–1687. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Soti C, Vermes A, Haystead TA and Csermely
P: Comparative analysis of the ATP-binding sites of Hsp90 by
nucleotide affinity cleavage: A distinct nucleotide specificity of
the C-terminal ATP-binding site. Eur J Biochem. 270:2421–2428.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sreedhar AS, Kalmar E, Csermely P and Shen
YF: Hsp90 isoforms: Functions, expression and clinical importance.
FEBS Lett. 562:11–15. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tsutsumi S, Mollapour M, Prodromou C, Lee
CT, Panaretou B, Yoshida S, Mayer MP and Neckers LM: Charged linker
sequence modulates eukaryotic heat shock protein 90 (Hsp90)
chaperone activity. Proc Natl Acad Sci USA. 109:2937–2942. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rowlands M, McAndrew C, Prodromou C, Pearl
L, Kalusa A, Jones K, Workman P and Aherne W: Detection of the
ATPase activity of the molecular chaperones Hsp90 and Hsp72 using
the TranscreenerTM ADP assay kit. J Biomol Screen. 15:279–286.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wandinger SK, Richter K and Buchner J: The
Hsp90 chaperone machinery. J Biol Chem. 283:18473–18477. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ali MM, Roe SM, Vaughan CK, Meyer P,
Panaretou B, Piper PW, Prodromou C and Pearl LH: Crystal structure
of an Hsp90-nucleotide-p23/Sba1 closed chaperone complex. Nature.
440:1013–1017. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Richter K, Soroka J, Skalniak L, Leskovar
A, Hessling M, Reinstein J and Buchner J: Conserved conformational
changes in the ATPase cycle of human Hsp90. J Biol Chem.
283:17757–17765. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Terasawa K, Minami M and Minami Y:
Constantly updated knowledge of Hsp90. J Biochem. 137:443–447.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Meyer P, Prodromou C, Liao C, Hu B, Roe
SM, Vaughan CK, Vlasic I, Panaretou B, Piper PW and Pearl LH:
Structural basis for recruitment of the ATPase activator Aha1 to
the Hsp90 chaperone machinery. EMBO J. 23:1402–1410. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Langer T, Rosmus S and Fasold H:
Intracellular localization of the 90 kDA heat shock protein
(HSP90alpha) determined by expression of a EGFP-HSP90alpha-fusion
protein in unstressed and heat stressed 3T3 cells. Cell Biol Int.
27:47–52. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang X, Song X, Zhuo W, Fu Y, Shi H, Liang
Y, Tong M, Chang G and Luo Y: The regulatory mechanism of
Hsp90alpha secretion and its function in tumor malignancy. Proc
Natl Acad Sci USA. 106:21288–21293. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sidera K, Samiotaki M, Yfanti E, Panayotou
G and Patsavoudi E: Involvement of cell surface HSP90 in cell
migration reveals a novel role in the developing nervous system. J
Biol Chem. 279:45379–45388. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tsutsumi S and Neckers L: Extracellular
heat shock protein 90: A role for a molecular chaperone in cell
motility and cancer metastasis. Cancer Sci. 98:1536–1539. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Stellas D, Karameris A and Patsavoudi E:
Monoclonal antibody 4C5 immunostains human melanomas and inhibits
melanoma cell invasion and metastasis. Clin Cancer Res.
13:1831–1838. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Eletto D, Dersh D and Argon Y: GRP94 in ER
quality control and stress responses. Semin Cell Dev Biol.
21:479–485. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hua G, Zhang Q and Fan Z: Heat shock
protein 75 (TRAP1) antagonizes reactive oxygen species generation
and protects cells from granzyme M-mediated apoptosis. J Biol Chem.
282:20553–20560. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sciacovelli M, Guzzo G, Morello V, Frezza
C, Zheng L, Nannini N, Calabrese F, Laudiero G, Esposito F,
Landriscina M, et al: The mitochondrial chaperone TRAP1 promotes
neoplastic growth by inhibiting succinate dehydrogenase. Cell
Metab. 17:988–999. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Masgras I, Sanchez-Martin C, Colombo G and
Rasola A: The chaperone TRAP1 as a modulator of the mitochondrial
adaptations in cancer cells. Front Oncol. 7:582017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhao R, Davey M, Hsu YC, Kaplanek P, Tong
A, Parsons AB, Krogan N, Cagney G, Mai D, Greenblatt J, et al:
Navigating the chaperone network: An integrative map of physical
and genetic interactions mediated by the hsp90 chaperone. Cell.
120:715–727. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Pratt WB, Morishima Y and Osawa Y: The
Hsp90 chaperone machinery regulates signaling by modulating ligand
binding clefts. J Biol Chem. 283:22885–22889. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zuehlke A and Johnson JL: Hsp90 and
co-chaperones twist the functions of diverse client proteins.
Biopolymers. 93:211–217. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Diaz-Villanueva JF, Diaz-Molina R and
Garcia-Gonzalez V: Protein folding and mechanisms of proteostasis.
Int J Mol Sci. 16:17193–17230. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Pearl LH, Prodromou C and Workman P: The
Hsp90 molecular chaperone: An open and shut case for treatment.
Biochem J. 410:439–453. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Trepel J, Mollapour M, Giaccone G and
Neckers L: Targeting the dynamic HSP90 complex in cancer. Nat Rev
Cancer. 10:537–549. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Neckers L and Workman P: Hsp90 molecular
chaperone inhibitors: Are we there yet? Clin Cancer Res. 18:64–76.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Garg G, Khandelwal A and Blagg BS:
Anticancer inhibitors of Hsp90 function: Beyond the usual suspects.
Adv Cancer Res. 129:51–88. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Neckers L, Mimnaugh E and Schulte TW:
Hsp90 as an anti-cancer target. Drug Resist Updat. 2:165–172. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Modi S, Stopeck A, Linden H, Solit D,
Chandarlapaty S, Rosen N, D'Andrea G, Dickler M, Moynahan ME,
Sugarman S, et al: HSP90 inhibition is effective in breast cancer:
A phase II trial of tanespimycin (17-AAG) plus trastuzumab in
patients with HER2-positive metastatic breast cancer progressing on
trastuzumab. Clin Cancer Res. 17:5132–5139. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ishikawa Y, Kozakai T, Morita H, Saida K,
Oka S and Masuo Y: Rapid detection of mycoplasma contamination in
cell cultures using SYBR Green-based real-time polymerase chain
reaction. In Vitro Cell Dev Biol Anim. 42:63–69. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Miyata Y, Nakamoto H and Neckers L: The
therapeutic target Hsp90 and cancer hallmarks. Curr Pharm Des.
19:347–365. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Barrott JJ and Haystead TA: Hsp90, an
unlikely ally in the war on cancer. FEBS J. 280:1381–1396. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Mori M, Hitora T, Nakamura O, Yamagami Y,
Horie R, Nishimura H and Yamamoto T: Hsp90 inhibitor induces
autophagy and apoptosis in osteosarcoma cells. Int J Oncol.
46:47–54. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Ciocca DR and Calderwood SK: Heat shock
proteins in cancer: Diagnostic, prognostic, predictive, and
treatment implications. Cell Stress Chaperones. 10:86–103. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Jafari A, Rezaei-Tavirani M,
Farhadihosseinabadi B, Taranejoo S and Zali H: HSP90 and
Co-chaperones: Impact on tumor progression and prospects for
molecular-targeted cancer therapy. Cancer Invest. 38:310–328. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Birbo B, Madu EE, Madu CO, Jain A and Lu
Y: Role of HSP90 in cancer. Int J Mol Sci. 22:103172021. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Pick E, Kluger Y, Giltnane JM, Moeder C,
Camp RL, Rimm DL and Kluger HM: High HSP90 expression is associated
with decreased survival in breast cancer. Cancer Res. 67:2932–2937.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Cheng Q, Chang JT, Geradts J, Neckers LM,
Haystead T, Spector NL and Lyerly HK: Amplification and high-level
expression of heat shock protein 90 marks aggressive phenotypes of
human epidermal growth factor receptor 2 negative breast cancer.
Breast Cancer Res. 14:R622012. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Moran Luengo T, Mayer MP and Rudiger SGD:
The Hsp70-Hsp90 chaperone cascade in protein folding. Trends Cell
Biol. 29:164–177. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Kamal A, Thao L, Sensintaffar J, Zhang L,
Boehm MF, Fritz LC and Burrows FJ: A high-affinity conformation of
Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature.
425:407–410. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Moulick K, Ahn JH, Zong H, Rodina A,
Cerchietti L, Gomes DaGama EM, Caldas-Lopes E, Beebe K, Perna F,
Hatzi K, et al: Affinity-based proteomics reveal cancer-specific
networks coordinated by Hsp90. Nat Chem Biol. 7:818–826. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Ferrarini M, Heltai S, Zocchi MR and
Rugarli C: Unusual expression and localization of heat-shock
proteins in human tumor cells. Int J Cancer. 51:613–619. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Sims JD, McCready J and Jay DG:
Extracellular heat shock protein (Hsp)70 and Hsp90alpha assist in
matrix metalloproteinase-2 activation and breast cancer cell
migration and invasion. PLoS One. 6:e188482011. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Cheng CF, Fan J, Fedesco M, Guan S, Li Y,
Bandyopadhyay B, Bright AM, Yerushalmi D, Liang M, Chen M, et al:
Transforming growth factor alpha (TGFalpha)-stimulated secretion of
HSP90alpha: Using the receptor LRP-1/CD91 to promote human skin
cell migration against a TGFbeta-rich environment during wound
healing. Mol Cell Biol. 28:3344–3358. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Eustace BK, Sakurai T, Stewart JK,
Yimlamai D, Unger C, Zehetmeier C, Lain B, Torella C, Henning SW,
Beste G, et al: Functional proteomic screens reveal an essential
extracellular role for hsp90 alpha in cancer cell invasiveness. Nat
Cell Biol. 6:507–514. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Gorska M, Popowska U, Sielicka-Dudzin A,
Kuban-Jankowska A, Sawczuk W, Knap N, Cicero G and Wozniak F:
Geldanamycin and its derivatives as Hsp90 inhibitors. Front Biosci
(Landmark Ed). 17:2269–2277. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
68
|
Samuni Y, Ishii H, Hyodo F, Samuni U,
Krishna MC, Goldstein S and Mitchell JB: Reactive oxygen species
mediate hepatotoxicity induced by the Hsp90 inhibitor geldanamycin
and its analogs. Free Radic Biol Med. 48:1559–1563. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Biamonte MA, Van de Water R, Arndt JW,
Scannevin RH, Perret D and Lee WC: Heat shock protein 90:
Inhibitors in clinical trials. J Med Chem. 53:3–17. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Ronnen EA, Kondagunta GV, Ishill N,
Sweeney SM, Deluca JK, Schwartz L, Bacik J and Motzer RJ: A phase
II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients
with papillary and clear cell renal cell carcinoma. Invest New
Drugs. 24:543–546. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Solit DB, Osman I, Polsky D, Panageas KS,
Daud A, Goydos JS, Teitcher J, Wolchok JD, Germino FJ, Krown SE, et
al: Phase II trial of 17-allylamino-17-demethoxygeldanamycin in
patients with metastatic melanoma. Clin Cancer Res. 14:8302–8307.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Heath EI, Hillman DW, Vaishampayan U,
Sheng S, Sarkar F, Harper F, Gaskins M, Pitot HC, Tan W, Ivy SP, et
al: A phase II trial of 17-allylamino-17-demethoxygeldanamycin in
patients with hormone-refractory metastatic prostate cancer. Clin
Cancer Res. 14:7940–7946. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Hanson BE and Vesole DH: Retaspimycin
hydrochloride (IPI-504): A novel heat shock protein inhibitor as an
anticancer agent. Expert Opin Investig Drugs. 18:1375–1383. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Kim YS, Alarcon SV, Lee S, Lee MJ,
Giaccone G, Neckers L and Trepel JB: Update on Hsp90 inhibitors in
clinical trial. Curr Top Med Chem. 9:1479–1492. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Wagner AJ, Chugh R, Rosen LS, Morgan JA,
George S, Gordon M, Dunbar J, Normant E, Grayzel D and Demetri GD:
A phase I study of the HSP90 inhibitor retaspimycin hydrochloride
(IPI-504) in patients with gastrointestinal stromal tumors or
soft-tissue sarcomas. Clin Cancer Res. 19:6020–6029. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Floris G, Sciot R, Wozniak A, Van Looy T,
Wellens J, Faa G, Normant E, Debiec-Rychter M and Schoffski P: The
Novel HSP90 inhibitor, IPI-493, is highly effective in human
gastrostrointestinal stromal tumor xenografts carrying
heterogeneous KIT mutations. Clin Cancer Res. 17:5604–5614. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Mellatyar H, Talaei S,
Pilehvar-Soltanahmadi Y, Barzegar A, Akbarzadeh A, Shahabi A,
Barekati-Mowahed M and Zarghami N: Targeted cancer therapy through
17-DMAG as an Hsp90 inhibitor: Overview and current state of the
art. Biomed Pharmacother. 102:608–617. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Wright L, Barril X, Dymock B, Sheridan L,
Surgenor A, Beswick M, Drysdale M, Collier A, Massey A, Davies N,
et al: Structure-activity relationships in purine-based inhibitor
binding to HSP90 isoforms. Chem Biol. 11:775–785. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Lundgren K, Zhang H, Brekken J, Huser N,
Powell RE, Timple N, Busch DJ, Neely L, Sensintaffar JL, Yang YC,
et al: BIIB021, an orally available, fully synthetic small-molecule
inhibitor of the heat shock protein Hsp90. Mol Cancer Ther.
8:921–929. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Dickson MA, Okuno SH, Keohan ML, Maki RG,
D'Adamo DR, Akhurst TJ, Antonescu CR and Schwartz GK: Phase II
study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal
tumors. Ann Oncol. 24:252–257. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Yan L, Zhang W, Zhang B, Xuan C and Wang
D: BIIB021: A novel inhibitor to heat shock protein 90-addicted
oncology. Tumour Biol. 39:10104283176983552017. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Hong D, Said R, Falchook G, Naing A,
Moulder S, Tsimberidou AM, Galluppi G, Dakappagari N, Storgard C,
Kurzrock R and Rosen LS: Phase I study of BIIB028, a selective heat
shock protein 90 inhibitor, in patients with refractory metastatic
or locally advanced solid tumors. Clin Cancer Res. 19:4824–4831.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Caldas-Lopes E, Cerchietti L, Ahn JH,
Clement CC, Robles AI, Rodina A, Moulick K, Taldone T, Gozman A,
Guo Y, et al: Hsp90 inhibitor PU-H71, a multimodal inhibitor of
malignancy, induces complete responses in triple-negative breast
cancer models. Proc Natl Acad Sci USA. 106:8368–8373. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Cerchietti LC, Lopes EC, Yang SN, Hatzi K,
Bunting KL, Tsikitas LA, Mallik A, Robles AI, Walling J,
Varticovski L, et al: A purine scaffold Hsp90 inhibitor
destabilizes BCL-6 and has specific antitumor activity in
BCL-6-dependent B cell lymphomas. Nat Med. 15:1369–1376. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Ambati SR, Lopes EC, Kosugi K, Mony U,
Zehir A, Shah SK, Taldone T, Moreira AL, Meyers PA, Chiosis G, et
al: Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone
and in combination with bortezomib in Ewing sarcoma. Mol Oncol.
8:323–336. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Fadden P, Huang KH, Veal JM, Steed PM,
Barabasz AF, Foley B, Hu M, Partridge JM, Rice J, Scott A, et al:
Application of chemoproteomics to drug discovery: Identification of
a clinical candidate targeting hsp90. Chem Biol. 17:686–694. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Huang KH, Veal JM, Fadden RP, Rice JW,
Eaves J, Strachan JP, Barabasz AF, Foley BE, Barta TE, Ma W, et al:
Discovery of novel 2-aminobenzamide inhibitors of heat shock
protein 90 as potent, selective and orally active antitumor agents.
J Med Chem. 52:4288–4305. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Cheung KM, Matthews TP, James K, Rowlands
MG, Boxall KJ, Sharp SY, Maloney A, Roe SM, Prodromou C, Pearl LH,
et al: The identification, synthesis, protein crystal structure and
in vitro biochemical evaluation of a new 3,4-diarylpyrazole class
of Hsp90 inhibitors. Bioorg Med Chem Lett. 15:3338–3343. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Brough PA, Aherne W, Barril X, Borgognoni
J, Boxall K, Cansfield JE, Cheung KM, Collins I, Davies NG,
Drysdale MJ, et al: 4,5-diarylisoxazole Hsp90 chaperone inhibitors:
Potential therapeutic agents for the treatment of cancer. J Med
Chem. 51:196–218. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Eccles SA, Massey A, Raynaud FI, Sharp SY,
Box G, Valenti M, Patterson L, de Haven Brandon A, Gowan S, Boxall
F, et al: NVP-AUY922: A novel heat shock protein 90 inhibitor
active against xenograft tumor growth angiogenesis, and metastasis.
Cancer Res. 68:2850–2860. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Jensen MR, Schoepfer J, Radimerski T,
Massey A, Guy CT, Brueggen J, Quadt C, Buckler A, Cozens R,
Drysdale MJ, et al: NVP-AUY922: A small molecule HSP90 inhibitor
with potent antitumor activity in preclinical breast cancer models.
Breast Cancer Res. 10:R332008. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Murray CW, Carr MG, Callaghan O, Chessari
G, Congreve M, Cowan S, Coyle JE, Downham R, Figueroa E,
Frederickson M, et al: Fragment-based drug discovery applied to
Hsp90. Discovery of two lead series with high ligand efficiency. J
Med Chem. 53:5942–5955. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Wang Y, Trepel JB, Neckers LM and Giaccone
G: STA-9090, a small-molecule Hsp90 inhibitor for the potential
treatment of cancer. Curr Opin Investig Drugs. 11:1466–1476.
2010.PubMed/NCBI
|
|
94
|
Nakashima T, Ishii T, Tagaya H, Seike T,
Nakagawa H, Kanda Y, Akinaga S, Soga S and Shiotsu Y: New molecular
and biological mechanism of antitumor activities of KW-2478, a
novel nonansamycin heat shock protein 90 inhibitor, in multiple
myeloma cells. Clin Cancer Res. 16:2792–2802. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Cavenagh J, Oakervee H, Baetiong-Caguioa
P, Davies F, Gharibo M, Rabin N, Kurman M, Novak B, Shiraishi N,
Nakashima D, et al: A phase I/II study of KW-2478, an Hsp90
inhibitor, in combination with bortezomib in patients with
relapsed/refractory multiple myeloma. Br J Cancer. 117:1295–1302.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Chang X, Zhao X, Wang J, Ding S, Xiao L,
Zhao E and Zheng X: Effect of Hsp90 inhibitor KW-2478 on HepG2
cells. Anticancer Agents Med Chem. 19:2231–2242. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Yong K, Cavet J, Johnson P, Morgan G,
Williams C, Nakashima D, Akinaga S, Oakervee H and Cavenagh J:
Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with
B-cell malignancies. Br J Cancer. 114:7–13. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Huang W, Ye M, Zhang LR, Wu QD, Zhang M,
Xu JH and Zheng W: FW-04-806 inhibits proliferation and induces
apoptosis in human breast cancer cells by binding to N-terminus of
Hsp90 and disrupting Hsp90-Cdc37 complex formation. Mol Cancer.
13:1502014. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Huang W, Wu QD, Zhang M, Kong YL, Cao PR,
Zheng W, Xu JH and Ye M: Novel Hsp90 inhibitor FW-04-806 displays
potent antitumor effects in HER2-positive breast cancer cells as a
single agent or in combination with lapatinib. Cancer Lett.
356:862–871. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Suda A, Koyano H, Hayase T, Hada K,
Kawasaki K, Komiyama S, Hasegawa K, Fukami TA, Sato S, Miura T, et
al: Design and synthesis of novel macrocyclic
2-amino-6-arylpyrimidine Hsp90 inhibitors. Bioorg Med Chem Lett.
22:1136–1141. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Bussenius J, Blazey CM, Aay N, Anand NK,
Arcalas A, Baik T, Bowles OJ, Buhr CA, Costanzo S, Curtis JK, et
al: Discovery of XL888: A novel tropane-derived small molecule
inhibitor of HSP90. Bioorg Med Chem Lett. 22:5396–5404. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Samarasinghe B, Wales CT, Taylor FR and
Jacobs AT: Heat shock factor 1 confers resistance to Hsp90
inhibitors through p62/SQSTM1 expression and promotion of
autophagic flux. Biochem Pharmacol. 87:445–455. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Soti C, Racz A and Csermely P: A
Nucleotide-dependent molecular switch controls ATP binding at the
C-terminal domain of Hsp90. N-terminal nucleotide binding unmasks a
C-terminal binding pocket. J Biol Chem. 277:7066–7075. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Schulte TW, Akinaga S, Soga S, Sullivan W,
Stensgard B, Toft D and Neckers LM: Antibiotic radicicol binds to
the N-terminal domain of Hsp90 and shares important biologic
activities with geldanamycin. Cell Stress Chaperones. 3:100–108.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Donnelly A and Blagg BS: Novobiocin and
additional inhibitors of the Hsp90 C-terminal nucleotide-binding
pocket. Curr Med Chem. 15:2702–2717. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Buchner J: Bacterial Hsp90-desperately
seeking clients. Mol Microbiol. 76:540–544. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Yun BG, Huang W, Leach N, Hartson SD and
Matts RL: Novobiocin induces a distinct conformation of Hsp90 and
alters Hsp90-cochaperone-client interactions. Biochemistry.
43:8217–8229. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Zhao J, Zhao H, Hall JA, Brown D, Brandes
E, Bazzill J, Grogan PT, Subramanian C, Vielhauer G, Cohen MS and
Blagg BS: Triazole containing novobiocin and biphenyl amides as
Hsp90 C-Terminal inhibitors. Medchemcomm. 5:1317–1323. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Astl L, Stetz G and Verkhivker GM:
Dissecting molecular principles of the Hsp90 chaperone regulation
by allosteric modulators using a hierarchical simulation approach
and network modeling of allosteric interactions: Conformational
selection dictates the diversity of protein responses and
ligand-specific functional mechanisms. J Chem Theory Comput.
16:6656–6677. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Marcu MG, Chadli A, Bouhouche I, Catelli M
and Neckers LM: The heat shock protein 90 antagonist novobiocin
interacts with a previously unrecognized ATP-binding domain in the
carboxyl terminus of the chaperone. J Biol Chem. 275:37181–37186.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Forsberg LK, Anyika M, You Z, Emery S,
McMullen M, Dobrowsky RT and Blagg BSJ: Development of
noviomimetics that modulate molecular chaperones and manifest
neuroprotective effects. Eur J Med Chem. 143:1428–1435. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Kumar Mv V, Ebna Noor R, Davis RE, Zhang
Z, Sipavicius E, Keramisanou D, Blagg BSJ and Gelis I: Molecular
insights into the interaction of Hsp90 with allosteric inhibitors
targeting the C-terminal domain. Medchemcomm. 9:1323–1331. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Rahimi MN and McAlpine SR: Protein-protein
inhibitor designed de novo to target the MEEVD region on the
C-terminus of Hsp90 and block co-chaperone activity. Chem Commun
(Camb). 55:846–849. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Huo Y, Buckton LK, Bennett JL, Smith EC,
Byrne FL, Hoehn KL, Rahimi MN and McAlpine SR: Delivering bioactive
cyclic peptides that target Hsp90 as prodrugs. J Enzyme Inhib Med
Chem. 34:728–739. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Rahimi MN, Foster HG, Farazi SN, Chapman R
and McAlpine SR: Polymer mediated transport of the Hsp90 inhibitor
LB76, a polar cyclic peptide, produces an Hsp90 cellular phenotype.
Chem Commun (Camb). 55:4515–4518. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Subramanian C, Grogan PT, Wang T, Bazzill
J, Zuo A, White PT, Kalidindi A, Kuszynski D, Wang G, Blagg BSJ and
Cohen MS: Novel C-terminal heat shock protein 90 inhibitors target
breast cancer stem cells and block migration, self-renewal, and
epithelial-mesenchymal transition. Mol Oncol. 14:2058–2068. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Subramanian C, Kovatch KJ, Sim MW, Wang G,
Prince ME, Carey TE, Davis R, Blagg BSJ and Cohen MS: Novel
C-Terminal heat shock protein 90 inhibitors (KU711 and Ku757) are
effective in targeting head and neck squamous cell carcinoma cancer
stem cells. Neoplasia. 19:1003–1011. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
White PT, Subramanian C, Zhu Q, Zhang H,
Zhao H, Gallagher R, Timmermann BN, Blagg BS and Cohen MS: Novel
HSP90 inhibitors effectively target functions of thyroid cancer
stem cell preventing migration and invasion. Surgery. 159:142–151.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Samadi AK, Zhang X, Mukerji R, Donnelly
AC, Blagg BS and Cohen MS: A novel C-terminal HSP90 inhibitor KU135
induces apoptosis and cell cycle arrest in melanoma cells. Cancer
Lett. 312:158–167. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Shelton SN, Shawgo ME, Matthews SB, Lu Y,
Donnelly AC, Szabla K, Tanol M, Vielhauer GA, Rajewski RA, Matts
RL, et al: KU135, a novel novobiocin-derived C-terminal inhibitor
of the 90-kDa heat shock protein, exerts potent antiproliferative
effects in human leukemic cells. Mol Pharmacol. 76:1314–1322. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Nirmalanandhan VS, Duren A, Hendricks P,
Vielhauer G and Sittampalam GS: Activity of anticancer agents in a
three-dimensional cell culture model. Assay Drug Dev Technol.
8:581–590. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Cohen SM, Mukerji R, Samadi AK, Zhang X,
Zhao H, Blagg BS and Cohen MS: Novel C-terminal Hsp90 inhibitor for
head and neck squamous cell cancer (HNSCC) with in vivo efficacy
and improved toxicity profiles compared with standard agents. Ann
Surg Oncol. 19 (Suppl 3):S483–S490. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Hyun SY, Le HT, Nguyen CT, Yong YS, Boo
HJ, Lee HJ, Lee JS, Min HY, Ann J, Chen J, et al: Development of a
novel Hsp90 inhibitor NCT-50 as a potential anticancer agent for
the treatment of non-small cell lung cancer. Sci Rep. 8:139242018.
View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Li W, Sahu D and Tsen F: Secreted heat
shock protein-90 (Hsp90) in wound healing and cancer. Biochim
Biophys Acta. 1823:730–741. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Biswas C, Ostrovsky O, Makarewich CA,
Wanderling S, Gidalevitz T and Argon Y: The peptide-binding
activity of GRP94 is regulated by calcium. Biochem J. 405:233–241.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Ernst JT, Liu M, Zuccola H, Neubert T,
Beaumont K, Turnbull A, Kallel A, Vought B and Stamos D:
Correlation between chemotype-dependent binding conformations of
HSP90α/β and isoform selectivity-Implications for the
structure-based design of HSP90α/β selective inhibitors for
treating neurodegenerative diseases. Bioorg Med Chem Lett.
24:204–208. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Putcha P, Danzer KM, Kranich LR, Scott A,
Silinski M, Mabbett S, Hicks CD, Veal JM, Steed PM, Hyman BT and
McLean PJ: Brain-permeable small-molecule inhibitors of Hsp90
prevent alpha-synuclein oligomer formation and rescue
alpha-synuclein-induced toxicity. J Pharmacol Exp Ther.
332:849–857. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Ernst JT, Neubert T, Liu M, Sperry S,
Zuccola H, Turnbull A, Fleck B, Kargo W, Woody L, Chiang P, et al:
Identification of novel HSP90α/β isoform selective inhibitors using
structure-based drug design. demonstration of potential utility in
treating CNS disorders such as Huntington's disease. J Med Chem.
57:3382–3400. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Ohkubo S, Kodama Y, Muraoka H,
Hitotsumachi H, Yoshimura C, Kitade M, Hashimoto A, Ito K, Gomori
A, Takahashi K, et al: TAS-116, a highly selective inhibitor of
heat shock protein 90α and β, demonstrates potent antitumor
activity and minimal ocular toxicity in preclinical models. Mol
Cancer Ther. 14:14–22. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Shimomura A, Yamamoto N, Kondo S, Fujiwara
Y, Suzuki S, Yanagitani N, Horiike A, Kitazono S, Ohyanagi F, Doi
T, et al: First-in-human phase I study of an oral HSP90 inhibitor,
TAS-116, in patients with advanced solid tumors. Mol Cancer Ther.
18:531–540. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Doi T, Kurokawa Y, Sawaki A, Komatsu Y,
Ozaka M, Takahashi T, Naito Y, Ohkubo S and Nishida T: Efficacy and
safety of TAS-116, an oral inhibitor of heat shock protein 90, in
patients with metastatic or unresectable gastrointestinal stromal
tumour refractory to imatinib, sunitinib and regorafenib: A phase
II, single-arm trial. Eur J Cancer. 121:29–39. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Rosser MF and Nicchitta CV: Ligand
interactions in the adenosine nucleotide-binding domain of the
Hsp90 chaperone, GRP94. I. Evidence for allosteric regulation of
ligand binding. J Biol Chem. 275:22798–22805. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Duerfeldt AS, Peterson LB, Maynard JC, Ng
CL, Eletto D, Ostrovsky O, Shinogle HE, Moore DS, Argon Y,
Nicchitta CV and Blagg BS: Development of a Grp94 inhibitor. J Am
Chem Soc. 134:9796–9804. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Patel PD, Yan P, Seidler PM, Patel HJ, Sun
W, Yang C, Que NS, Taldone T, Finotti P, Stephani RA, et al:
Paralog-selective Hsp90 inhibitors define tumor-specific regulation
of HER2. Nat Chem Biol. 9:677–684. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Crowley VM, Khandelwal A, Mishra S,
Stothert AR, Huard DJ, Zhao J, Muth A, Duerfeldt AS, Kizziah JL,
Liebermann RL, et al: Development of glucose regulated protein
94-selective inhibitors based on the bnim and radamide scaffold. J
Med Chem. 59:3471–3488. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Jiang F, Guo AP, Xu JC, You QD and Xu XL:
Discovery of a Potent Grp94 selective inhibitor with
anti-inflammatory efficacy in a mouse model of ulcerative colitis.
J Med Chem. 61:9513–9533. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Plescia J, Salz W, Xia F, Pennati M,
Zaffaroni N, Daidone MG, Meli M, Dohi T, Fortugno P, Nefedova Y, et
al: Rational design of shepherdin, a novel anticancer agent. Cancer
Cell. 7:457–468. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Altieri DC, Stein GS, Lian JB and Languino
LR: TRAP-1, the mitochondrial Hsp90. Biochim Biophys Acta.
1823:767–773. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Lee C, Park HK, Jeong H, Lim J, Lee AJ,
Cheon KY, Kim CS, Thomas AP, Bae B, Kim ND, et al: Development of a
mitochondria-targeted Hsp90 inhibitor based on the crystal
structures of human TRAP1. J Am Chem Soc. 137:4358–4367. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Park HK, Jeong H, Ko E, Lee G, Lee JE, Lee
SK, Lee AJ, Im JY, Hu S, Kim SH, et al: Paralog specificity
determines subcellular distribution, action mechanism, and
anticancer activity of TRAP1 inhibitors. J Med Chem. 60:7569–7578.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Sveen A, Bruun J, Eide PW, Eilertsen IA,
Ramirez L, Murumagi A, Arjama M, Danielsen SA, Kryeziu K, Elez E,
et al: Colorectal cancer consensus molecular subtypes translated to
preclinical models uncover potentially targetable cancer cell
dependencies. Clin Cancer Res. 24:794–806. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Piper PW and Millson SH: Mechanisms of
resistance to Hsp90 inhibitor drugs: A complex mosaic emerges.
Pharmaceuticals (Basel). 4:1400–1422. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Bendell JC, Jones SF, Hart L, Pant S,
Moyhuddin A, Lane CM, Earwood C, Murphy P, Patton J, Penley WC, et
al: A Phase I Study of the Hsp90 inhibitor AUY922 plus capecitabine
for the treatment of patients with advanced solid tumors. Cancer
Invest. 33:477–482. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Wang Y, Koay YC and McAlpine SR: How
selective are Hsp90 inhibitors for cancer cells over normal cells?
Chem Med Chem. 12:353–357. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Mohammadian M, Feizollahzadeh S, Mahmoudi
R, Toofani Milani A, Rezapour-Firouzi S and Karimi Douna B: Hsp90
Inhibitor; NVP-AUY922 in combination with doxorubicin induces
apoptosis and downregulates VEGF in MCF-7 breast cancer cell line.
Asian Pac J Cancer Prev. 21:1773–1778. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Tse AN, Klimstra DS, Gonen M, Shah M,
Sheikh T, Sikorski R, Carvajal R, Mui J, Tipian C, O'Reilly E, et
al: A phase 1 dose-escalation study of irinotecan in combination
with 17-allylamino-17-demethoxygeldanamycin in patients with solid
tumors. Clin Cancer Res. 14:6704–6711. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Sulthana S, Banerjee T, Kallu J, Vuppala
SR, Heckert B, Naz S, Shelby T, Yambem O and Santra S: Combination
therapy of NSCLC using Hsp90 inhibitor and doxorubicin carrying
functional nanoceria. Mol Pharm. 14:875–884. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Ono N, Yamazaki T, Tsukaguchi T, Fujii T,
Sakata K, Suda A, Tsukuda T, Mio T, Ishii N, Kondoh O and Aoki Y:
Enhanced antitumor activity of erlotinib in combination with the
Hsp90 inhibitor CH5164840 against non-small-cell lung cancer.
Cancer Sci. 104:1346–1352. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Feng Q, Zhang C, Lum D, Druso JE, Blank B,
Wilson KF, Welm A, Antonyak MA and Cerione RA: A class of
extracellular vesicles from breast cancer cells activates VEGF
receptors and tumour angiogenesis. Nat Commun. 8:144502017.
View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Johnson ML, Yu HA, Hart EM, Weitner BB,
Rademaker AW, Patel JD, Kris MG and Riely GJ: Phase I/II study of
HSP90 inhibitor AUY922 and erlotinib for EGFR-Mutant lung cancer
with acquired resistance to epidermal growth factor receptor
tyrosine kinase inhibitors. J Clin Oncol. 33:1666–1673. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Meehan R, Kummar S, Do K, O'Sullivan Coyne
G, Juwara L, Zlott J, Rubinstein L, Doroshow JH and Chen AP: A
Phase I Study of ganetespib and Ziv-Aflibercept in patients with
advanced carcinomas and sarcomas. Oncologist. 23:1269–e1125. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Lee HJ, Shin S, Kang J, Han KC, Kim YH,
Bae JW and Park KH: HSP90 Inhibitor, 17-DMAG, alone and in
combination with lapatinib attenuates acquired lapatinib-resistance
in ER-positive, HER2-overexpressing breast cancer cell line.
Cancers (Basel). 12:26302020. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Jhaveri K and Modi S: HSP90 inhibitors for
cancer therapy and overcoming drug resistance. Adv Pharmacol.
65:471–517. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Chen F, Xie H, Bao H, Violetta L and Zheng
S: Combination of HSP90 and autophagy inhibitors promotes
hepatocellular carcinoma apoptosis following incomplete thermal
ablation. Mol Med Rep. 22:337–343. 2020.PubMed/NCBI
|
|
155
|
Vaishampayan UN, Burger AM, Sausville EA,
Heilbrun LK, Li J, Horiba MN, Egorin MJ, Ivy P, Pacey S and Lorusso
PM: Safety, efficacy, pharmacokinetics, and pharmacodynamics of the
combination of sorafenib and tanespimycin. Clin Cancer Res.
16:3795–3804. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Kawazoe A, Itahashi K, Yamamoto N, Kotani
D, Kuboki Y, Taniguchi H, Harano K, Naito Y, Suzuki M, Fukutani M,
et al: TAS-116 (Pimitespib), an Oral HSP90 inhibitor, in
combination with nivolumab in patients with colorectal cancer and
other solid tumors: An open-label, dose-finding, and expansion
Phase Ib trial (EPOC1704). Clin Cancer Res. 27:6709–6715. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Roué G, Pérez-Galán P, Mozos A,
López-Guerra M, Xargay-Torrent S, Rosich L, Saborit-Villarroya I,
Normant E, Campo E and Colomer D: The Hsp90 inhibitor IPI-504
overcomes bortezomib resistance in mantle cell lymphoma in vitro
and in vivo by down-regulation of the prosurvival ER chaperone
BiP/Grp78. Blood. 117:1270–1279. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Ishii T, Seike T, Nakashima T, Juliger S,
Maharaj L, Soga S, Akinaga S, Cavenagh J, Joel S and Shiotsu Y:
Anti-tumor activity against multiple myeloma by combination of
KW-2478, an Hsp90 inhibitor, with bortezomib. Blood Cancer J.
2:e682012. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Mbofung RM, McKenzie JA, Malu S, Zhang M,
Peng W, Liu C, Kuiatse I, Tieu T, Williams L, Devi S, et al: HSP90
inhibition enhances cancer immunotherapy by upregulating interferon
response genes. Nat Commun. 8:4512017. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Proia DA and Kaufmann GF: Targeting
heat-shock protein 90 (HSP90) as a complementary strategy to immune
checkpoint blockade for cancer therapy. Cancer Immunol Res.
3:583–589. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Rao A, Taylor JL, Chi-Sabins N, Kawabe M,
Gooding WE and Storkus WJ: Combination therapy with HSP90 inhibitor
17-DMAG reconditions the tumor microenvironment to improve
recruitment of therapeutic T cells. Cancer Res. 72:3196–3206. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Spiegelberg D, Dascalu A, Mortensen AC,
Abramenkovs A, Kuku G, Nestor M and Stenerlow B: The novel HSP90
inhibitor AT13387 potentiates radiation effects in squamous cell
carcinoma and adenocarcinoma cells. Oncotarget. 6:35652–35666.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Spiegelberg D, Abramenkovs A, Mortensen
ACL, Lundsten S, Nestor M and Stenerlow B: The HSP90 inhibitor
Onalespib exerts synergistic anti-cancer effects when combined with
radiotherapy: An in vitro and in vivo approach. Sci Rep.
10:59232020. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Naz S, Banerjee T, Totsingan F, Woody K,
Gross RA and Santra S: Therapeutic efficacy of lactonic
sophorolipids: Nanoceria-assisted combination therapy of NSCLC
using HDAC and Hsp90 inhibitors. Nanotheranostics. 5:391–404. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Lin TY, Guo W, Long Q, Ma A, Liu Q, Zhang
H, Huang Y, Chandrasekaran S, Pan C, Lam KS, et al: HSP90 inhibitor
encapsulated photo-theranostic nanoparticles for synergistic
combination cancer therapy. Theranostics. 6:1324–1335. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Bradbury AR and Marks JD: Antibodies from
phage antibody libraries. J Immunol Methods. 290:29–49. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Saw PE and Song EW: Phage display
screening of therapeutic peptide for cancer targeting and therapy.
Protein Cell. 10:787–807. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Wang J, Masehi-Lano JJ and Chung EJ:
Peptide and antibody ligands for renal targeting: Nanomedicine
strategies for kidney disease. Biomater Sci. 5:1450–1459. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Fosgerau K and Hoffmann T: Peptide
therapeutics: Current status and future directions. Drug Discov
Today. 20:122–128. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Petters E, Sokolowska-Wedzina A and
Otlewski J: Selection and characterization of single chain antibody
fragments specific for Hsp90 as a potential cancer targeting
molecule. Int J Mol Sci. 16:19920–19935. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Mochizuki K, Matsukura L, Ito Y, Miyashita
N and Taki M: A medium-firm drug-candidate library of cryptand-like
structures on T7 phage: Design and selection of a strong binder for
Hsp90. Org Biomol Chem. 19:146–150. 2021. View Article : Google Scholar : PubMed/NCBI
|
